Treatment‐Specific Clinical and Urinary Biomarker Signatures Associated With Response to Intravesical Botulinum Toxin A and Platelet‐Rich Plasma in Bladder Pain Syndrome

To estimate response to intravesical onabotulinumtoxinA (BoNT‐A) injection and platelet‐rich plasma (PRP) therapy in females with bladder pain syndrome (BPS) without Hunner lesions, we developed and internally validated treatment‐specific predictive models integrating clinical characteristics, bladder functional parameters, and urinary biomarkers.